-AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS
-Phase 1 LUMINA trial of AMX0114 underway; early cohort data expected in 2025
Morning ID2T ,,
They did 2 weeks agoAmylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
Great to see some SH value clocking up again on the SP ....
Hoping like everyone else a Commercial Partners signs ASAP as the money clock never stops , NUZ need funds by the end of the month IMHO the next 4C has to show more than 2Q of funding ASX wont be overly keen on allowing 2Q to be below the regulated amount...
Just needs some wet ink on a freshly printed contract.. Boom
Mind you lets not forget NUZ is pushing well $80m MC as it's still only at Phase I , safety and tolerability data in hand...
Pre-clinicals ,,additional OLE ...
Best of Luck to all Invested NZT
